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Recent ﬁndings on the role of transforming growth factor (TGF)-b/Smad3 signaling in the pathogenesis of obesity and type 2
diabetes have underscored its importance in metabolism and adiposity. Indeed, elevated TGF-b has been previously reported
in human adipose tissue during morbid obesity and diabetic neuropathy. In this review, we discuss the pleiotropic effects of
TGF-b/Smad3 signaling on metabolism and energy homeostasis, all of which has an important part in the etiology and
progression of obesity-linked diabetes; these include adipocyte differentiation, white to brown fat phenotypic transition,
glucose and lipid metabolism, pancreatic function, insulin signaling, adipocytokine secretion, inﬂammation and reactive oxygen
species production. We summarize the recent in vivo ﬁndings on the role of TGF-b/Smad3 signaling in metabolism based on
the studies using Smad3
 /  mice. Based on the presence of a dual regulatory effect of Smad3 on peroxisome proliferator-
activated receptor (PPAR)b/d and PPARg2 promoters, we propose a unifying mechanism by which this signaling pathway
contributes to obesity and its associated diabetes. We also discuss how the inhibition of this signaling pathway has been
implicated in the amelioration of many facets of metabolic syndromes, thereby offering novel therapeutic avenues for these
metabolic conditions.
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INTRODUCTION
Obesity has become a global epidemic over the past decades.
Obesity is associated with an array of secondary metabolic
abnormalities, including insulin resistance, type 2 diabetes
and hyperlipidemia, which are collectively termed metabolic
syndrome.
1 Type 2 diabetes has afﬂicted a staggering 180 million
people worldwide, and its associated complications, including
diabetic nephropathy, extremity amputation and heart failure,
have become the principal contributors of morbidity and mortality
in the western world.
2 The mechanisms by which obesity causes
insulin resistance and type 2 diabetes, as well as the pathological
events that occur during this process, have been vigorously
studied.
3 Dynamic interactions among different metabolic organs,
such as the pancreas, skeletal muscle, liver and adipose tissue,
have a key role in the pathogenesis of obesity and diabetes. The
hallmark events involved in the development of obesity-linked
diabetes include elevation of plasma free fatty acid (FFA), ectopic
lipid accumulation in metabolic organs, chronic low-grade
inﬂammation in adipose tissue, peripheral insulin resistance,
chronic hyperglycemia and eventual pancreatic b-cell dysfunc-
tion.
3 These seemingly independent events are actually inter-
connected in terms of their etiology and downstream effects.
Indeed, recent studies have investigated the molecular
and genetic basis that governs the whole-body response to this
disease. However, many questions remain unsolved. Recent novel
ﬁndings on the involvement of transforming growth factor
(TGF)-b/Smad3 signaling in the pathogenesis of obesity and type
2 diabetes have shed some light on its roles in adipose physiology
and metabolism.
4- -6 Several groups of researchers have recently
demonstrated that TGF-b/Smad3 signaling regulates insulin
gene transcription in the pancreatic islet b-cells,
7 whereas
Smad3 deﬁciency in mice protects against insulin resistance
and type 2 diabetes during high-fat diet-induced obesity.
4,5
These Smad3-knockout (Smad3
 / ) mice exhibited diminished
adiposity with improved glucose tolerance and insulin sensitiv-
ity.
4,5 These mutant mice also displayed increased b-oxidation in
the adipose tissue upon administration of a high-fat diet, thus
ameliorating gluco- and lipotoxicity in the pancreas, skeletal
muscle and liver by preventing ectopic fat accumulation.
4 In
addition, Smad3 gene deletion in mice triggered a brown
phenotypic transformation and elevated mitochondrial biogenesis
in the white adipose tissue (WAT), thereby allowing for the
dissipation of the excess energy stored in fat by thermogenesis.
5
Notably, when TGF-b/Smad3 signaling was blunted by treatment
with a TGF-b neutralizing antibody, it protected the mice from
obesity and type 2 diabetes.
5 These ﬁndings indicate that Smad3,
the canonical intracellular mediator of TGF-b, serves as a multi-
faceted regulator of metabolic homeostasis, thus identifying
Smad3 as a potential target in the treatment of obesity and its
associated disorders.
In this review, we discuss the molecular mechanisms by which
TGF-b/Smad3 signaling contributes to the pathogenesis of obesity
and diabetes, including systemic glucose and lipid metabolism,
pancreatic b-cell function, adipocyte differentiation, white-to-
brown fat transformation, reactive oxygen species (ROS) produc-
tion, adipocytokine secretion and inﬂammation. Here, we review
current ﬁndings regarding the role of TGF-b/Smad3 in metabolism
and discuss how the inhibition of this signaling pathway has been
proposed to ameliorate many facets of metabolic syndromes.
These ﬁndings discussed here support that TGF-b/Smad3 signal-
ing has a crucial role in the events leading to obesity-linked
diabetes by acting as the molecular intersection point where
a number of pathological events converge. We attempt
to summarize the systemic actions of TGF-b/Smad3, thereby
identifying the plausible therapeutic avenues for the treatment of
these diseases.
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TGF-b1 is the prototype of a superfamily of highly conserved and
structurally related secreted cytokines, which also includes the
bone morphogenetic proteins, activins/inhibins and myostatin.
These pleiotropic cytokines regulate a plethora of biological
processes during embryogenesis and adult tissue homeostasis,
such as cell proliferation, differentiation and speciﬁcation
of developmental fate.
8 Particularly, TGF-b1 has a central role in
ﬁbrosis, contributing to the inﬁltration and activation of inﬂam-
matory cells, ﬁbroblasts and matrix remodeling.
8 TGF-b1 signals
through a complex of two membrane-bound receptor serine/
threonine kinases, the TGF-b type I and type II receptors, which
recruit and phosphorylate receptor-activated Smads, including
Smad2 and Smad3, the canonical intracellular mediators of TGF-b
(Figure 1). Smads are modular proteins with two well-conserved
domains, the N-terminal Mad-homology-1 domain and the
C-terminal Mad-homology-2 domain, joined together by a pro-
line-rich linker region (Figure 1).
9 A Ser-Ser-X-Ser motif is located
at the extreme C-terminal end of the Smad3.
9 In cell signaling
pathways, various transcription factors are phosphorylated at
multiple sites by upstream kinases. TGF-b type I receptors, activin
type IB and IC receptors phosphorylate the C-terminal Ser-Ser-X-
Ser motif of Smad2 and Smad3, whereas mitogenic signals
alternatively cause the phosphorylation of receptor-activated
Smads at speciﬁc sites in their linker regions.
10 Once phosphory-
lated, Smad2 and Smad3 oligomerize with Smad4 before their
translocation into the nucleus, where they bind to DNA to
modulate transcriptional events.
9 Smad2 and Smad3 have
apparently distinct functions, although they share 490% homol-
ogy in their amino-acid sequences.
11 The essential role of Smad2
in embryonic development was initially revealed by embryonic
lethality in Smad2-knockout mice at embryonic days 7.5--12.5.
12
In contrast, Smad3
 /  mice are viable and exhibit postnatal
growth retardation, immune defects and accelerated wound
healing.
13,14 Smad3
 /  mice are also resistant to radiation- and
chemical-induced ﬁbrosis and other ﬁbrotic disorders, such as
scleroderma and cystic ﬁbrosis.
15
The systemic impact of TGF-b/Smad3 deﬁciency in the etiology
of metabolic syndrome has recently been uncovered. Emerging
evidence has implicated TGF-b1 in obesity and diabetes. For
instance, an increased activation of the TGF-b/Smad3 signaling
pathway was detected in the WAT of Lep
ob/ob mice.
6 Elevated
TGF-b1 in humans have been shown to positively correlate with
increased adiposity, a poor metabolic proﬁle and negatively
correlate with ﬁtness.
5 TGF-b1 level in adipose tissue and body
mass index are closely associated in individuals with morbid
obesity.
16 Further, plasma TGF-b are also augmented in hyperten-
sion and other cardiovascular diseases, indicative of its role in
metabolic syndrome.
17 Elevated TGF-b1 have been associated
with a higher risk for type 2 diabetes in a prospective case-cohort
study.
18 Moreover, the Smad3 gene was identiﬁed in a type 2
diabetes genome-wide association study.
19 Treatment with anti-
TGF-b antibodies protects genetically and diet-induced obese
mice from obesity and type 2 diabetes.
5 TGF-b signaling has also
been implicated in glucose-induced cell hypertrophy upon
prolonged exposure to glucose, which may result in complications
associated with pancreatic b-cell dysfunction and insulin resis-
tance.
20 Polymorphisms in TGF-b1, for example, T29C polymorph-
ism that results in a Leu-Pro substitution at the signal peptide, as
well as elevated circulating TGF-b are correlated with increased
body mass index, elevated fasting insulin and glucose, insulin
resistance, as well as predisposition to cardiovascular disorders.
21,22
The Leu-Pro substitution disrupts the hydrophobicity and overall
structure of core signal sequence to affect production of TGF-b1.
23
Renal expression of TGF-b1 was upregulated in diabetic humans,
24
whereas early manifestations of diabetic renal disease in mice can
be prevented by systemic treatment with anti-TGF-b antibodies
and antisense TGF-b1 oligodeoxynucleotides.
25,26
ADIPOCYTE DIFFERENTIATION AND LIPID METABOLISM
Obesity is medically deﬁned as a state of excessive body fat
accumulation to an extent that produces adverse health
consequences. In times of nutrient abundance, a positive energy
balance occurs when the energy intake exceeds the energy
expenditure, leading to a net storage of surplus energy in the
form of triglycerides in adipose tissue. Adipose tissue mass is
dependent on both the size and number of its constituent
Figure 1. TGF-b/Smad canonical signaling pathway. The TGF-b1 signals through a complex of TGF-b type I (TGFbRI) and type II receptors that
recruit and activate intracellular mediator Smads, such as Smad2 and Smad3, which translocate into the nucleus transcriptionally regulate
gene expression.
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distinct processes, namely hypertrophy (increase in cell size) and
hyperplasia (increase in cell number). Adipocyte hypertrophy is
achieved in mature adipocytes via an increase in lipid accumu-
lation or lipogenesis (i.e., triglyceride synthesis), which are
synergetic with a decrease in lipolysis (i.e., triglyceride break-
down). In contrast, adipocyte hyperplasia relies on a complicated
process called adipogenesis that involves preadipocyte differen-
tiation. Among the many transcriptional cascades controlling
adipogenesis, peroxisome proliferator-activated receptor (PPAR)g2
is well characterized as the master regulator of the adipogenic
program.
27 Upon exposure to adipogenic hormones, such
as glucocorticoids, cyclic AMP and insulin, the expression of
transcription factors CCAAT/enhancer-binding protein (C/EBP)b
and C/EBPd is transiently increased during adipocyte differentia-
tion. Together they induce PPARg2 expression in the
preadipocytes, subsequently triggering full-blown adipocyte
differentiation.
27 PPARg2, a nuclear hormone receptor, hetero-
dimerizes with the retinoid X receptor and induces the expression
of C/EBPa, which subsequently takes over the function of C/EBPb
and C/EBPd in maintaining the transcription of PPARg2 via a
positive feedback mechanism.
27 Activated C/EBPa cooperates
with PPARg2 to induce the expression of other adipogenic genes
involved in the differentiation program.
Previous in vitro studies showed that TGF-b1 inhibits adipogen-
esis independently of the Wnt/b-catenin signaling pathway and
through the inhibitory effects of its downstream mediator Smad3
on the transactivational potential of C/EBPs, thus abolishing the
subsequent activation of PPARg2.
6,28 Retinoic acid (RA) inhibits
adipogenesis and its action appears to block C/EBPb transcrip-
tional potential early during differentiation. This RA-mediated
effect has also been found to be dependent on Smad3.
29 A recent
ﬁnding also revealed an important role of cellular RA-binding
protein-II in regulating the transcriptional activity of RA through
RA receptor. The early and sustained repression of cellular
RA-binding protein-II by glucocorticoid receptor and C/EBPa,
respectively, is critical for adipogenesis.
30 However, recent in vivo
and in vitro studies using Smad3
 /  mice have demonstrated a
paradoxical role of TGF-b/Smad3 as an activator of adipocyte
differentiation.
4,5 Primary mouse embryonic ﬁbroblasts extracted
from Smad3
 /  mice display marked impairment in their ability to
differentiate into white adipocytes and show reduced expression
of WAT-speciﬁc genes.
5 This is consistent with the observations
that Smad3
 /  mice exhibit dramatic reduction in adiposity as a
result of decreased adipocyte number and size,
4 suggesting
the presence of defective adipogenesis and lipid accumulation
in these mice. Gene expression proﬁling of the Smad3
 /  WAT
revealed decreased expression of PPARg2 transcripts, which
coincided with an increased expression of the preadipocyte-
speciﬁc marker preadipocyte factor-1.
4 Lipid accumulation relies
on the process of lipogenesis, which involves de novo synthesis of
fatty acids (FAs) and glycerol, FA uptake and triglyceride synthesis.
In fact, PPARg2 not only participates in adipocyte differentiation
and survival, but it also promotes lipid accumulation by activating
target genes involved in lipogenesis, such as FA synthase, adipose
FA-binding protein and phosphoenolpyruvate carboxykinase.
31
Except for FA uptake, the expression of the rate-limiting enzymes
involved in lipogenesis (e.g., FA synthase, acetyl-CoA carboxylase-1
and stearoyl-CoA desaturase-1) and triglyceride synthesis
(e.g., diacylglycerol O-acyltransferase-1 and -2) was concomitantly
downregulated in the Smad3
 /  WAT as evidence by decrease in
ex vivo triglyceride synthesis.
4 In contrast with the diminished
PPARg2 expression, a marked augmentation in the expression
level of PPARb/d and its regulated genes, such as uncoupling
protein (UCP)-2, UCP-3 and acyl-CoA oxidase (ACOX)-1, has also
been found in the Smad3
 /  WAT.
4 This is in agreement with the
ﬁnding that ex vivo FA b-oxidation was elevated in the Smad3
 / 
WAT.
4 The activation of PPARb/d in obese mice has been shown
to selectively induce the expression of genes required for FA
b-oxidation and energy dissipation, such as UCPs and ACOX-1, but
not genes involved in lipogenesis and fat storage, which are
controlled by PPARg2.
32 The underlying mechanism behind this
disparate effect of Smad3 on fat storage and burning involves the
dual effects of Smad3 deﬁciency on the PPARg2 and PPARb/d
promoters. Chromatin immunoprecipitation and re-chromatin
immunoprecipitation assays showed that C/EBPb was associated
with a speciﬁc C/EBP binding site at 494--485bp upstream from
the PPARb/d promoter, thereby resulting in the recruitment to this
element of a transcriptional repressor complex containing histone
deacetylase 1 and the repression of PPARb/d.
4 Besides, C/EBPb can
freely bind to the PPARg2 promoter to exert its adipogenic and
lipogenic effects in normal WAT.
4 In contrast, Smad3 deﬁciency
leads to upregulation of an anti-adipogenic factor C/EBP
homologous protein-10, which directly binds to C/EBPb to
liberate PPARb/d transcription while impeding PPARg2 activation
(Figure 2).
4 This ﬁnding is further validated by the fact that C/EBP
homologous protein-10 acts as a dominant-negative inhibitor
of C/EBP by preventing its binding to DNA.
33
Figure 2. TGF-b/Smad3 signaling promotes adipocyte differentiation but inhibits FA b-oxidation and thermogenesis.
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have catastrophic consequences for Smad3
 /  mice if not for
the increased FA uptake and b-oxidation. This concern over the
adverse effects of fat storage depletion stems from the fat-storing
functions of adipose tissue that prevent the ectopic lipid
accumulation and lipotoxicity in metabolic organs, for example,
hepatic steatosis. Indeed, ablation of PPARg2 in obese mice results
in reduced fat mass but leads to severe insulin resistance,
pancreatic b-cell failure and dyslipidemia due to the cumulative
deposition of toxic lipid reactive species in the peripheral
organs.
34 Moreover, intramuscular triglyceride content has
previously been reported to be elevated in diabetic patients and
inversely correlated with the degree of insulin resistance.
35
Nonetheless, these abnormalities were not observed in
Smad3
 /  mice probably because of the decreased lipolysis and
increased FA uptake from the circulation, ultimately targeting
FAs for b-oxidation and energy dissipation in WAT (Figure 3).
4
This hypothesis is substantiated by the ﬁndings that Smad3
 / 
Figure 3. (a) Systemic role of TGF-b/Smad3 signaling in the pathogenesis of type 2 diabetes. (b) Amelioration of type 2 diabetes upon
blockade of TGF-b/Smad3 signaling.
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of FAs and triglyceride in the peripheral organs upon high-fat diet
treatment.
4 Despite the fact that skeletal muscle is the organ
responsible for most of the body energy expenditure and ablation
of PPARb/d in skeletal muscle has been shown to induce a
muscle ﬁber-type switching toward a lower oxidative capacity
that precedes the development of obesity and diabetes.
36,37 It is
unlikely that increased FA b-oxidation in skeletal muscle
contributes to the antidiabetic phenotypes in Smad3
 /  mice
because of the presence of muscular atrophy and constant
PPARb/d mRNA expression level in skeletal muscle of these
animals.
4,38 This is consistent with an unaltered metabolic rate in
Smad3
 /  mice, reﬂecting a balance between their reduced
physical activity and increased adipose lipid oxidation.
4 In
conjunction, a role for TGF-b/Smad3 in b2-adrenergic-induced
muscle hypertrophy, satellite cell function and myogenic differ-
entiation has also been reported.
38,39 Although WAT is not a major
energy consumer compared with skeletal muscle, increased FA
b-oxidation in WAT can have a profound impact on adiposity and
insulin sensitivity.
40 Clearly, adipose tissue is the primary tissue
responsible for the antiobesity effects of Smad3 deﬁciency
because FA oxidation is not altered in the liver of Smad3
 / 
mice.
4 Interestingly, a WAT-to-brown adipose tissue (BAT)
phenotypic switch has been reported recently in Smad3
 /  mice
and in adipocytes transfected with silencing short-hairpin RNA
targeting Smad3.
5 The mRNA expression level of PPARg2 is barely
detectable whereas that of PPARg1 is expressed at a low level in
rodent and human skeletal muscle.
41- -44 Hence, the effect of
Smad3 on PPARg2 and PPARb/d promoters is likely to be present
predominantly in WAT where PPARg2 is abundantly expressed.
To date, no data has indicated a similar regulatory effect of Smad3
on the PPARg1 promoters in the skeletal muscle.
WAT-TO-BAT PHENOTYPIC TRANSITION
There are two major types of adipose tissues in mammals, white
and brown. WAT is pale white in color and is comprised
predominantly of large unilocular adipocytes that are specialized
for fat storage. Conversely, BAT possesses a dark-red color because
of its high-mitochondrial content, and it consists of small-
multilocular adipocytes that are highly adapted for oxidizing
chemical energy for heat production through a process called
thermogenesis. Brown adipocytes express UCP-1, which uncou-
ples respiration from ATP synthesis, allowing for heat production.
PR domain containing 16 (PRDM16) is a transcriptional coregulator
that governs the development of brown adipocytes in classic BAT
depots such as peri-renal and interscapular brown fats.
45 White
and brown adipocytes were previously believed to originate from
a common lineage, however, several studies have countered this
assumption.
46,47 A common lineage for muscle and BAT has been
proposed based on the ﬁndings that speciﬁc cells derived from
the dermomyotome give rise to muscle and brown adipocytes but
not white fat cells.
47 Further evidence stems from the expression
of myogenic factor (Myf)-5, which links muscle and brown fat cells
and excludes white adipocytes.
46,48 In addition, in vivo lineage
tracing has identiﬁed muscle and brown adipocytes as the only
cell types in which Myf5 promoter is induced.
46 This conclusion
was conﬁrmed by the conversion of cultured myoblasts into
brown adipocytes upon ectopic expression of PRDM16 and
the reversal of primary brown adipocytes to myocytes with the
knockdown of PRDM16.
46 Despite the evidence supporting the
theory of the common lineage of muscle/brown adipocytes, it is
also clear that a population of distinctive, recruitable Myf5-
negative cells is interspersed in the WAT. These cells are probably
derived from the activation of dormant precursor cells residing
within the WAT in response to environmental cues, such as
adrenergic stimulation or cold exposure.
46 In humans, depots of
WAT are found in different anatomical locations in the body, with
subcutaneous and visceral fat depots representing the major
compartments for fat storage. The accumulation of intra-
abdominal or visceral WAT, in particular, has been reported to
be the most strongly correlated with an elevated risk for metabolic
dysfunction and cardiovascular disease.
49 A transformation from
white to brown adipocytes in WAT has been reported in several
mouse knockout strains that exhibit resistance against diet-
induced obesity and type 2 diabetes.
50,51
Gross examination of the Smad3
 /  WAT reveals a beige
appearance resembling an intermediate tinge of white and brown.
The presence of smaller and multilocular adipocytes with
characteristics of brown adipocytes is evident within the milieu
of larger unilocular white adipocytes.
5 Gene expression proﬁling
conﬁrmed an increase in the transcript levels of brown adipogenic
markers, including PPARg coactivator-1a, UCP-1 and PRDM16 in
Smad3
 /  WAT.
5 Indeed, Smad3 was found to regulate PPARg
coactivator-1a promoter and PRDM16 target genes.
5 Ablation of
TGF-b/Smad3 signaling in normal WAT consistently induces the
mitochondrial, BAT and skeletal muscle-speciﬁc transcripts in vitro
and in vivo; whereas administration of exogenous TGF-b1i n
3T3-L1 preadipocytes results in elevation in WAT-speciﬁc tran-
scripts and a concurrent suppression of BAT/mitochondrial genes.
5
Smad3
 /  WAT also contained increased mitochondrial DNA copy
number, ATP content and mitochondria with densely packed
cristae, indicative of enhanced mitochondrial biogenesis and
function.
5 The physiological relevance of thermogenic activation
in Smad3
 /  mice is illustrated by their ability to maintain a higher
core temperature upon cold exposure and increased oxygen
consumption.
5 This may provide supports for the conclusion that
TGF-b/Smad3 has a crucial role in the recruitment and activation
of brown adipocytes in the white fat depots. However, the origin
and characteristics of these recruited brown adipocytes have yet
to be examined despite microarray analyses of Smad3
 /  WAT
and anti-TGF-b antibody-treated wild-type WAT have identiﬁed
genes involved in skeletal muscle biology, such as tropomyosin,
troponin and myosin.
5 This suggests the recruitment of a
myogenic lineage of brown adipocytes that expresses the Myf5
protein. Interestingly, Myf5 protein in the Smad3
 /  skeletal
muscle was found to be downregulated.
38 However, it should be
considered that the differential role of TGF-b/Smad3 may be
dependent on the tissue-speciﬁc context. Moreover, the detailed
molecular mechanism by which TGF-b/Smad3 signaling activates
the thermogenic program in WAT still remains elusive. The dual
effects of Smad3 on both PPARg2 and PPARb/d promoters may
provide an explanation for the anti-adipogenic and pro-thermo-
genic effects of the TGF-b/Smad3 signaling pathway (Figure 4).
This is substantiated by the ﬁndings that PPARb/d controls PPARg
coactivator-1a expression in the skeletal muscle to eradicate
obesity and diabetes by inducing a muscle ﬁber-type switch that
favors FA oxidation,
36 although the direct regulation of PPARg
coactivator-1a promoter by PPARb/d has not been examined in
WAT. Another approach that TGF-b/Smad3 may adopt to induce
browning in WAT is likely mediated through its interaction with
the b-adrenergic system, as indicated by a crosstalk between
TGF-b1 and b-adrenergic signaling pathways in cardiac
hypertrophy.
52 Lastly, the WAT-to-BAT phenotypic transition
observed in Smad3
 /  mice may be accountable for the increased
fat burning capacity, thus providing an alternative therapeutic
approach for tackling obesity and diabetes.
PANCREATIC FUNCTION, INSULIN SIGNALING AND
GLUCOSE METABOLISM
Pancreatic b-cells are remarkably plastic in their ability to regulate
insulin release in response to ﬂuctuations in plasma glucose level.
Most obese and insulin-resistant individuals do not initially
develop hyperglycemia, as pancreatic b-cells could provisionally
compensate for the reduced peripheral insulin sensitivity by
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circulation.
53 As the liver progressively develops insulin resistance
due to hepatic steatosis, hepatic gluconeogenesis is augmented
and an additional workload is placed upon the pancreas to
increase insulin supply to counter the hyperglycemia. For obesity
and insulin resistance to be linked with type 2 diabetes, pancreatic
b-cells have to become dysfunctional and decompensated
because of the chronic and synergistic effects of gluco- and
lipotoxicity on the b cells.
54 Although plasma FFA level is critical
for normal insulin secretion, chronic exposure of pancreatic b-cells
to FFAs in vivo and in vitro is associated with marked reductions in
glucose-stimulated insulin secretion and insulin biosynthesis.
55,56
Excessive intramuscular FFA and triglyceride accumulation have
also been shown to cause insulin resistance resulting from
the adverse effects of chronic lipotoxicity.
57 Recent studies have
indicated that FFAs induce insulin resistance in skeletal muscle by
blocking insulin activation of insulin receptor substrate (IRS)-1-
associated phosphatidylinositol 3-kinase via the increased activa-
tion of protein kinase C-y and the downstream phosphorylation of
IRS-1 at Ser (307), thereby decreasing the IRS-1 tyrosine
phosphorylation and the subsequent IRS-1-associated phosphati-
dylinositol 3-kinase activity.
58 This in turn decreases glucose
transporter-4 translocation, followed by decreased insulin-stimu-
lated glucose uptake. Furthermore, the liver is a key regulator of
glucose homeostasis because of its ability to store glucose as
glycogen postprandially or release glucose via gluconeogenesis
and glycogenolysis during starvation. Excessive intraperitoneal fat
has been proposed to induce hepatic steatosis and hepatic insulin
resistance via an increased inﬂux of FFA from the portal vein
directly to the liver.
59 In overnight-fasted rats, FFAs were shown to
increase basal endogenous glucose production and induce
hepatic insulin resistance through an increase in the in vivo
activity of glucose-6-phosphatase, an enzyme involved in the
rate-limiting step of gluconeogenesis and glycogenolysis, and
also through an impairment of in vivo glucokinase (a glycolytic
enzyme) activity, which is presumably due to an inhibitory
allosteric effect of fatty acyl-CoA (an activated form of FA) on
the enzyme activity.
60
The loss of Smad3 in mice causes a mild hypoglycemic
phenotype in these animals. These mice also exhibit enhanced
glucose tolerance and insulin hypersensitivity upon glucose and
insulin challenge.
4,5 Hyperinsulinemic-euglycemic clamp studies
and ex vivo tissue-speciﬁc glucose uptake assays further conﬁrmed
that glucose infusion rate required to maintain euglycemia was
higher in Smad3
 /  mice;
4 this was in parallel with an elevated
whole-body glucose uptake and an enhanced insulin-mediated
suppression of hepatic glucose output, suggesting that Smad3
deﬁciency results in whole-body enhanced insulin responsiveness
in WAT, skeletal muscle and liver (Figure 3).
4,5 Upon administration
of a high-fat diet, Smad3
 /  mice are resistant to the development
of obesity and type 2 diabetes, whereas wild-type mice become
obese and develop hyperinsulinemia, hepatic steatosis, hypergly-
cemia and insulin resistance as detected by glucose tolerance and
insulin sensitivity tests.
4,5 These results particularly indicate the
role of TGF-b/Smad3 signaling in the pathogenesis of obesity and
type 2 diabetes. Consistently, an elevation in protein expression
levels of the key mediators of insulin-signaling cascades has also
been found in the Smad3
 /  WAT and skeletal muscle.
4 Previous
studies indicate that insulin-mediated activation of protein kinase
B/Akt can inhibit TGF-b1 signaling by the formation of a protein
kinase B/Smad3 complex.
61 This interaction causes the inhibition
of Smad3-mediated gene regulation, thereby placing protein
kinase B-Smad3 at a point of convergence in the crosstalk
between TGF-b/Smad3 and insulin signaling pathways.
61 Chronic
hyperglycemia can cause tissue injury and one pathological
response to tissue injury is ﬁbrosis. Smad3 abrogation is likely to
prevent tissue injury and ﬁbrosis through its combined actions
against the development of hyperglycemia and ﬁbrotic
response in the face of chronic glucose exposure. The recently
described role of TGF-b/Smad3 signaling in glucose-induced cell
hypertrophy and damage may have ramiﬁcations for conditions
associated with insulin resistance and diabetes.
20 Fibrosis is
Figure 4. Proposed model for WAT-to-BAT phenotypic conversion upon loss of TGF-b/Smad3 signaling in adipocytes. This phenotypic
transformation is mediated, at least in part, through the dual effects of Smad3 on both the PPARb/d and PPARg2 promoters. Smad3 deﬁciency
promotes a brown phenotype in the WAT milieu.
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tissues. The development of liver ﬁbrosis is associated with insulin
resistance in hepatitis patients.
62 Smad3 has been identiﬁed as the
main mediator of the TGF-b pro-ﬁbrotic response, especially in
cirrhosis and other hepatic ﬁbrotic disorders.
15 It is possible that
Smad3 partially ameliorates hepatic insulin resistance by prevent-
ing glucotoxicity and its associated ﬁbrosis in the liver. Ablation of
Smad3 in mice also leads to hyperinsulinemia that may explain for
the hypoglycemic phenotype observed in these animals.
4,7 TGF-b/
Smad3 signaling is now known to repress insulin gene transcrip-
tion through direct binding of Smad3 to the insulin gene
promoter.
7 Therefore, the lack of Smad3-mediated repression of
insulin transcription from the pancreatic b-cells results in elevated
plasma insulin and mild hypoglycemia. Consistently, the expres-
sion level of genes involved in insulin biosynthesis, pro-insulin
processing, glucose metabolism, insulin exocytosis and glucose-
stimulated insulin secretion was concomitantly upregulated in the
Smad3
 /  b-cell islets, as supported by enhanced glucose-
stimulated insulin secretion ex vivo and in vivo.
7 Moreover,
TGF-b signaling has been implicated in pancreatic diseases and
development, as illustrated by the transgenic mice overexpressing
TGF-b1 in the b cells that display abnormal islet formation.
63 These
ﬁndings demonstrate the pivotal role of TGF-b/Smad3 in the
regulation of b-cell function and development, especially in the
setting of increased insulin demand, such as insulin resistance,
diabetes and during b-cell injury. Pharmaceutical inactivation of TGF-
b/Smad3 signaling might be useful for promoting b-cell differentia-
tion and ameliorating b-cell dysfunction during diabetes.
ADIPOCYTOKINE SECRETION AND INFLAMMATION
The WAT has traditionally been regarded solely as an energy
storage organ that accumulates triglycerides during times of
energy abundance and releases FFAs when energy expenditure
exceeds energy intake. However, over the last decades, a novel
role of adipose tissue as a dynamic endocrine organ has
emerged.
40 Adipose tissue is now known to secrete a myriad of
bioactive molecules that are collectively termed adipocytokines,
some of which have been shown to act in either an autocrine,
paracrine or endocrine fashion to affect glucose and lipid
homeostasis as well as insulin sensitivity.
64- -66 Among these
adipocytokines, tumor necrosis factor (TNF)-a, interleukin (IL)-6,
resistin, visfatin, leptin, monocyte chemoattractant protein
(MCP)-1, plasminogen activator inhibitor (PAI)-1, retinol-binding
protein-4 and adiponectin have been documented as active
modulators of peripheral insulin sensitivity and implicated in the
development of insulin resistance.
67 Adipocytokine secretion from
adipose tissue is perturbed during obesity, which in turn is
associated with diseases such as metabolic syndrome, insulin
resistance and cardiovascular disease.
67- -69 The mechanism by
which adipocytokines inﬂuence insulin resistance in obesity is still
not fully understood. However, accumulating evidence suggests
that obesity alters the amount and spectrum of adipocytokines
that are secreted from adipose tissue.
69 Indeed, a differential
expression of pro- and anti-inﬂammatory factors has been
associated with the sizes of adipocytes, whereby dysregulation
of hypertrophic adipocytes causes a shift toward dominance of
pro-inﬂammatory adipocytokines.
70 These pro-inﬂammatory adi-
pocytokines secreted from the hypertrophic adipocytes may be
involved in the development of a chronic low-grade inﬂammatory
state, which is considered to be the ‘common soil’ for the
pathogenesis of metabolic syndrome.
70 Adipose tissue from the
obese subjects secretes more pro-inﬂammatory cytokines, such as
TNF-a, IL-6 and MCP-1, as evidenced by their elevated concentra-
tions in the circulation.
66,71 Moreover, serum retinol-binding
protein-4 levels are elevated in insulin-resistant mice and humans
with obesity and type 2 diabetes.
72 Retinol-binding protein
signaling cascade also induces the expression of STAT target
genes, such as suppressor of cytokine signaling-3, which inhibits
insulin signaling.
73 An increase in the inﬁltration of macrophages
in WAT has also been reported in obesity, which partly contributes
to the pro-inﬂammatory cytokines secreted from the adipose
tissue.
66 Obesity has been demonstrated to induce inﬁltration of
macrophages with distinct gene expression characteristics and
cytokine secretion spectra to adipose tissue, thereby inducing a
phenotypic switch in the activation state of adipose tissue
macrophages from an anti-inﬂammatory M2-polarized state.
74,75
This state protects adipocytes from progression to an M1 pro-
inﬂammatory state, which contributes to insulin resistance.
74,75
Particularly, adipose tissue macrophages from lean mice express
many genes that are characteristic of the protective M2 or
‘alternatively activated’ macrophages, including Ym1, arginase 1
and IL-10; whereas those from diet-induced obese mice express
genes that are characteristic of the pro-inﬂammatory M1 or
‘classically activated’ macrophages, such as TNF-a and IL-6 that
promote inﬂammation.
74
Whole-body deletion of Smad3 in mice induces a lean
phenotype and enhanced insulin sensitivity regardless of feeding
regimen.
4,5 Smad3
 /  mice exhibit less inﬂammatory macrophage
inﬁltration into the WAT, with a switch in macrophage spectrum
from inﬂammatory M1 to protective M2 macrophages.
5 Smad3
 / 
WAT also shows augmented expression of insulin-mimetic visfatin
with a concomitant reduction in the expression of resistin, PAI-1
and pro-inﬂammatory cytokines, such as TNF-a, IL-6 and MCP-1 in
WAT as well as in the circulation.
4,5 Visfatin is predominantly
produced and secreted by the visceral WAT. Visfatin regulates
insulin secretion, insulin receptor signaling and mRNA expression
of diabetes-related genes in mouse pancreatic b-cells.
76 Human
resistin, on the contrary, has been found to impair insulin-
mediated glucose transport by reducing the intrinsic activity of
cell-surface glucose transporters and stimulating the production
and secretion of the pro-inﬂammatory cytokines TNF-a and IL-12
in macrophages via an NF-kB-dependent pathway.
77,78 Further-
more, increased TNF-a production has been observed in adipose
tissue isolated from obese rodents and human subjects.
79 Multiple
mechanisms have been proposed to account for the adverse
effects of TNF-a on insulin sensitivity; these include its direct
inhibitory action on insulin signaling, induction of elevated FFA via
stimulation of lipolysis and negative regulation of adipocyte
differentiation.
79 IL-6 is another adipocytokine similar to TNF-a
with regards to its deleterious effects on insulin signaling in the
liver, skeletal muscles and adipocytes via ubiquitin-mediated
degradation of IRS through suppressor of cytokine signaling-1 and
suppressor of cytokine signaling-3.
80,81
As discussed previously, inﬁltration of macrophages into
adipose tissue is an important determinant of the increased
inﬂammatory process in obesity. Adipocytes secrete an array of
chemoattractants that draw monocytes from the circulation into
the adipose tissue. MCP-1, also known as chemokine (C--C motif)
ligand (CCL)-2, is one of the chemoattractants secreted by
adipocytes that has a pivotal role in macrophage recruitment.
Indeed, elevated plasma MCP-1 and its overexpression in adipose
tissue have been found in obese humans and subjects with insulin
resistance.
71,82 Mice lacking MCP-1 or its receptor (CCR-2) exhibit
reduced adipose tissue macrophage inﬁltration and ameliorated
insulin resistance and hepatic steatosis.
66,83 Although there is no
evidence supporting the notion that TGF-b/Smad3 signaling
directly modulates MCP-1 expression in adipose tissue, MCP-1
has been previously shown to be a direct gene target of TGF-b by
Smad3/4 in endothelial cells.
84 PAI-1 gene expression, which is
governed by TGF-b through the binding of phosphorylated
Smad2/3 to its promoter, is also highly induced in subjects with
metabolic complications of obesity.
85,86 PAI-1 acts as an inhibitor
of ﬁbrinolysis by inhibiting both tissue-type and urokinase-type
plasminogen activators through its serine protease inhibitor
function. Its aberrant expression in obesity has a detrimental
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ischemic diseases. The expression of leptin in WAT of Smad3
 / 
mice was also found to be downregulated when compared with
their wild-type counterparts despite similar caloric intake between
these mice.
5 Leptin has a key role in energy homeostasis by
binding to receptors in the hypothalamus of the brain where it
inhibits appetite and induces the feeling of satiety.
87 Further,
genetic abnormalities in leptin or its receptors in rodents revealed
obesity-related deﬁcits in macrophage phagocytosis and the
expression of pro-inﬂammatory cytokines both in vivo and in vitro,
whereas treatment with exogenous leptin rescued these deﬁcits in
inﬂammation.
88 The mechanism by which TGF-b/Smad3 signaling
affects leptin promoter activity has not been elucidated in vivo,
although an in vitro study reported an opposite and inhibitory
action of TGF-b/Smad3 on leptin promoter mediated by
sequestration of C/EBPb.
28 Moreover, it is noteworthy to highlight
that adiponectin may also contribute to the antidiabetic effects of
Smad3
 /  mice, although its plasma concentration and expression
level in Smad3
 /  WAT have yet to be determined. This hypo-
thesis is supported by the ﬁndings that FFAs impair adiponectin
bioactivity in hepatocytes via TGF-b-mediated pathway and that
smaller adipocytes (as seen in Smad3
 /  mice) secrete more
adiponectin than do larger cells.
89,90 Adiponectin improves insulin
sensitivity by increasing energy expenditure and FA oxidation
through the activation of AMP-activated protein kinase and by
increasing the expression of PPARa target genes, such as CD36,
ACOX and UCP-2.
91 Indeed, the mRNA transcript and protein levels
of ACOX and UCP-2 have been shown to be markedly upregulated
in the WAT of Smad3
 /  mice.
4 Interestingly, the TGF-b/Smad3
signaling pathway has been reported to directly suppress PPARa
activity to reduce FA oxidation in cardiac myocytes.
92 It is plausible
that augmented FA b-oxidation in the WAT of Smad3
 /  mice may
act through an AMP-activated protein kinase- and/or PPARa-
mediated mechanism by the autocrine effect of adiponectin.
However, except for PAI-1 and leptin, no results have shown
that the TGF-b/Smad3 signaling pathway directly regulates the
production and secretion of these adipocytokines in adipose
tissue. Moreover, it is still unclear whether the protective effects of
Smad3 gene deletion or anti-TGF-b antibody treatment for insulin
resistance could be an immediate effect because of a change in
adipocytokine secretion as a consequence of altered inﬁltration of
macrophages or reduced adiposity (Figure 5).
TGF-b/SMAD3 AS THE LINK BETWEEN ROS AND INSULIN
RESISTANCE
ROS are generated as byproducts of normal cellular metabolism
and have important roles in cellular signaling and homeostasis.
93
In times of environmental stress (e.g., exposure to ultraviolet
radiation, heat exposure and hypoxia), ROS levels can be
dramatically increased. ROS are highly reactive because of the
presence of unpaired valence shell electrons, and this accounts for
their damaging effects on cellular molecules in a situation known
as oxidative stress. ROS are derived from the mitochondrial
respiration and the activity of NADPH oxidases and their
intracellular levels are constantly kept in check by the activity of
endogenous antioxidant enzymes such as Cu/Zn superoxide
dismutase (SOD), MnSOD and catalase, which catalyze the dismu-
tation of superoxide into oxygen and H2O2 and the conversion of
H2O2 to water and oxygen. ROS are among the many factors that
have previously been suggested to have a deleterious effect on
insulin resistance.
94 It is based on the evidence that oxidative
stress markers are associated with obesity and diabetes in
humans,
95,96 and insulin resistance is induced in 3T3-L1 adipo-
cytes upon treatment with H2O2 and ROS-inducing agents.
97 The
expression of oxidative stress markers has also been reported in
Lep
ob/ob mice with insulin resistance and glucose intolerance.
98
Additionally, chemical inhibitors of NADPH oxidase can improve
glucose homeostasis in an obese mouse model.
96 Metabolic
studies also demonstrate that individuals with primary defects
that affect the ROS balance, such as familiar amyotrophic lateral
sclerosis, develop insulin resistance.
99 ROS are now considered
to have a causal role in the etiology of insulin resistance.
100 An
in vitro study showed that ROS were markedly elevated in TNFa-
induced insulin resistance in 3T3-L1 adipocytes, and this increase
in ROS preceded the onset of insulin resistance.
100 In contrast,
administration of antioxidant N-acetylcysteine revealed an insulin-
sensitizing effect of this drug that leads to a dose-dependent
suppression of insulin resistance as determined by insulin-
stimulated glucose uptake in the cultured adipocytes.
100
Figure 5. Elevated TGF-b/Smad3 signaling causes adipocyte hypertrophy, hyperplasia and elevated pro-inﬂammatory cytokines production.
These cytokines interfere with insulin signaling and promote the recruitment of M1 pro-inﬂammatory macrophages to the WAT. Smad3
deﬁciency ameliorates the chronic low-grade inﬂammation and insulin resistance by recruiting M2 protective macrophages and reducing
pro-inﬂammatory cytokines expression from the adipocytes. Smad3 deﬁciency also upregulates the mRNA level of insulin-mimetic visfatin
while decreasing resistin (insulin-desentizer).
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enzymes Cu/ZnSOD, MnSOD and catalase exhibited reduced
TNFa-induced insulin resistance.
100 Little information is available
regarding the downstream pathways that translate elevated ROS
into insulin resistance. Studies indicate that c-Jun amino-terminal
kinase (JNK) signaling may be an attractive candidate, as JNK
activity is abnormally elevated by oxidative stress, inﬂammatory
cytokines and FFAs as well as in obesity.
101,102 JNK has been
shown to interfere with insulin signaling through its direct
association with IRS-1 and its subsequent phosphorylation
inhibition.
103 Inhibition of JNK activity through genetic knockout
improves insulin sensitivity in mouse models of obesity.
101
JNK and Smad3 cascades are essential components of the
TGF-b signaling machinery and have been implicated in common
transcriptional responses.
104 JNK has also been shown to induce
Smad3 phosphorylation at the site outside of its Ser-Ser-Val-Ser
motif.
104 This interdependent relationship between JNK and
Smad3 in mediating TGF-b response suggests that JNK may be
the intermediate player between TGF-b and Smad3 that links ROS
to the development of insulin resistance and type 2 diabetes.
Further, TGF-b has previously been shown to trigger intracellular
ROS release via redox- and Smad3-dependent upregulation of
NADPH oxidase 4 while inhibiting the expression of MnSOD and
catalase in asthmatic and obstructive airway smooth muscle.
105
TGF-b also mediates hepatocyte apoptosis through Smad3
generation of ROS.
106 The preponderance of evidence indicates
that TGF-b/Smad3 signaling has a major role in the regulation of
ROS production and its breakdown. However, there is no direct
evidence to support the claim that TGF-b/Smad3 regulates ROS
production to cause insulin resistance and type 2 diabetes.
Hypoxia may present another link between TGF-b and ROS in
insulin resistance. The rise in adipose mass during obesity may
result in hypoxia in clusters of adipocytes distant from the
vasculature, triggering inﬂammation serving to increase blood
ﬂow via angiogenesis. The response of TGF-b to hypoxia is
mediated through direct binding of Smad3 with hypoxia-inducible
factor-1a.
107 It is plausible that the hypoxic, overly expanded
adipocytes trigger ROS production either via a direct or a
TGF-b-mediated mechanism that ultimately leads to insulin
resistance. The explanation behind the protection against insulin
resistance and type 2 diabetes in Smad3
 /  mice could partially
be due to the decreased FFA and glucose, the small adipocyte size
and the reduced levels of inﬂammation that directly affect
the production of ROS. Indeed, increased FFA and glucose can
increase ROS production and oxidative stress.
96,97 ROS are likely to
inﬂuence insulin signaling in WAT, skeletal muscle and liver.
Further research will be needed to test this possibility.
TGF-b/SMAD3 SIGNALING AS ANTIDIABETIC DRUG TARGET
There are currently four different classes of antidiabetic drugs
available in the market: sulfonylureas, biguanides, acarbose and
thiazolidinediones (TZD). These drugs adopt several distinctive
approaches to deploy their antidiabetic effects, including
stimulation of insulin production from the pancreatic b-cells
(sulfonylureas), inhibition of hepatic gluconeogenesis (bigua-
nides), reduction of intestinal glucose digestion and absorption
(acarbose) and elimination of ectopic lipid build up in muscle and
liver by enhancing fat storage (TZD). Acarbose inhibits intestinal
a-glucosidase and pancreatic a-amylase to prevent digestion of
complex carbohydrates, thereby disrupting their subsequent
absorption in the small intestine. Meanwhile, sulfonylureas bind
to the ATP-depedent K
þ channels located on the plasma
membrane of pancreatic b-cells to induce insulin secretion from
the pancreatic b-cells. However, sulfonylureas are ineffective in
patients who have deﬁcits in insulin production, such as in type 1
diabetes and post-pancreatectomy. The side effects of acarbose
and sulfonylureas preclude their wide use in the treatment of
diabetes; these include hepatitis, cardiovascular risk and potential
teratogenicity. For these reasons, the biguanide class of antidia-
betic drugs, such as metformin, has been the ﬁrst-line drug
of choice and the most widely prescribed drug for the treatment
of type 2 diabetes despite its mild side effects. Metformin
improves hyperglycemia primarily through suppression of hepatic
gluconeogenesis mediated by AMP-activated protein kinase
activation.
108 TZD, which include troglitazone, rosiglitazone and
Figure 6. Summary of the whole-body effects of TGF-b/Smad3 signaling in obesity-linked diabetes and how blockage of TGF-b/Smad3
signaling ameliorates obesity and type 2 diabetes.
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improve insulin sensitivity by promoting lipid storage in adipose
tissue through the activation of PPARg.
109 Nonetheless, treatment
with TZD in diabetic individuals often results in weight gain,
although plasma FFA and peripheral ectopic lipid accumulation
are reduced.
110 An increased risk of bladder cancer risk among
diabetic patients treated with pioglitazone has also been reported
in a longitudinal cohort study.
111 Furthermore, the withdrawal of
troglitazone and rosiglitazone from the market in United States
and Europe, respectively, due to an increased incidence of
hepatitis and cardiovascular events has raised concerns over the
use of other TZDs.
Although most of the current obesity therapies aim to reduce
caloric intake, much attention is now focused on an alternative
strategy of increasing cellular energy expenditure. Because of
the presence of a host of undesirable effects associated with the
use of currently available antidiabetic drugs, there is a demand for
a better therapeutic target for the treatment of type 2 diabetes.
Targeting TGF-b/Smad3 signaling may represent a more holistic
approach in tackling these conditions (Figure 6). Indeed, Lep
ob/ob
and diet-induced obese mice treated with anti-TGF-b neutralizing
antibody exhibit weight loss, enhanced glucose tolerance and
insulin sensitivity, suppression of hepatic steatosis and reduced
blood glucose level, ultimately resulting in protection against
obesity and type 2 diabetes.
5 The beneﬁcial effects of TGF-b
antibody treatment rely on its ability to transform energy-storing
WAT into energy-dissipating BAT in obese and diabetic mouse
models.
5 Clinical use of TGF-b antagonist is now being evaluated
for the treatment of ﬁbrosis, scarring, cancer and diabetic
nephropathy where increased TGF-b are implicated. It is likely
that attention will be focused on their application in diabetes
treatment. Notably, a speciﬁc inhibitor of Smad3 (SIS3) has
recently been characterized as a potent and selective inhibitor of
Smad3 function in vitro.
112 Immunoprecipitation revealed that
SIS3 speciﬁcally attenuated the TGF-b1-induced phosphorylation
of Smad3 and its interaction with Smad4 in a dose-dependent
manner whereas Smad2 phosphorylation remained unaltered.
The biological relevance of SIS3 in Smad3 inhibition was further
conﬁrmed by evaluation of its ability to suppress the TGF-b1-
induced type I pro-collagen upregulation and myoﬁbroblast
differentiation in human dermal and scleroderma ﬁbroblasts.
113
Although SIS3 may seem to be a promising candidate for drug
development for diabetes treatment, its effects on glucose and
lipid metabolism remain elusive in vivo. Further effort should also
be focused on target speciﬁcation, as WAT is the primary target
responsible for the antidiabetic effects of TGF-b/Smad3 antagon-
ism. Particularly, Smad3 deletion in mice causes muscle atrophy
and defective immune response,
13,38 which may represent as
off-target effects if speciﬁcation of the TGF-b/Smad3 antagonist
is compromised. Gene therapy using short-hairpin RNA to
speciﬁcally target WAT may represent an attractive approach to
circumvent this problem. In support of this possibility, suppression
of Smad3 expression using lentivirus-based short-hairpin
RNA technology induces a WAT-to-BAT phenotypic switch and
thermogenic program in adipocyte cell lines.
5 Losartan, an
angiotensin II receptor type 1 receptor antagonist, is another
interesting candidate for antidiabetic drug development targeting
TGF-b. Losartan has been shown to decrease plasma TGF-b1
in transplant patients with chronic allograft nephropathy
and attenuate the development of obesity and insulin resistance
in diet-induced obese mice probably mediated through
downregulation of PAI-1 (a target gene of TGF-b/Smad3
signaling).
113- -120
CONCLUSION
In summary, TGF-b/Smad3 signaling regulates a wide range of
events involved in metabolism and the pathogenesis of obesity
and type 2 diabetes. Smad3
 /  mice provide an invaluable tool for
the elucidation of molecular mechanisms behind the diverse roles
of TGF-b1 in adipocyte differentiation, lipid and glucose metabo-
lism, white to brown fat transformation, pancreatic insulin
production, adipocytokine secretion, inﬂammatory cell recruit-
ment and ROS production (Figure 7). All of these processes have
profound impacts on the etiology of obesity and its associated
complications. Our knowledge on the mechanistic actions of
TGF-b/Smad3 signaling will certainly allow us to dissect and
understand the complicated processes involved during the
development of obesity and diabetes. The main theme behind
the recent ﬁndings suggests that TGF-b/Smad3 signaling may
represent a common site of intersection between the various
pathologies that comprise metabolic syndrome. Turning the ‘bad’
fat (fat-storing white adipocytes) into ‘good’ fat (fat-burning
brown adipocytes) will inevitably present a novel unifying
approach for the treatment of all facets of obesity and diabetes.
The availability of Smad3-speciﬁc inhibitors most certainly holds
the promise of lessening the burden of global epidemic of obesity
and diabetes.
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